A phase 2 study of Pelareorep in combination with standard of care therapy in the neoadjuvant setting in metastatic breast cancer (mBC ).
Phase of Trial: Phase II
Latest Information Update: 14 Mar 2018
At a glance
- Drugs Pelareorep (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 14 Mar 2018 New trial record
- 09 Mar 2018 According to an Oncolytics Biotech media release, this partner-sponsored window of opportunity study is expected to start in the second half of 2018.